Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults

Autor: Zhang, Yuntao, Yang, Yunkai, Qiao, Niu, Wang, Xuewei, Ding, Ling, Zhu, Xiujuan, Liang, Yu, Han, Zibo, Liu, Feng, Zhang, Xinxin, Yang, Xiaoming
Rok vydání: 2022
Předmět:
Zdroj: Frontiers of Medicine
ISSN: 2095-0225
2095-0217
DOI: 10.1007/s11684-021-0914-x
Popis: Inducing durable and effective immunity against severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) via vaccination is essential to combat the current pandemic of coronavirus disease 2019 (COVID-19). It has been noticed that the strength of anti-COVID-19 vaccination-induced immunity fades over time, which calls for an additional vaccination regime, as known as booster immunization, to restore immunity among previously vaccinated populations. Here we report a pilot open-label trial of a third dose of BBIBP-CorV, an inactivated SARS-CoV-2 vaccine (Vero cell), on 136 participants aged between 18 to 63 years. Safety and immunogenicity in terms of neutralizing antibody titers and cytokine/chemokine responses were analyzed as the main endpoint until day 28. While systemic reactogenicity was either absent or mild, SARS-CoV-2-specific neutralizing antibody titers rapidly arose in all participants within 4 weeks, surpassing the peak antibody titers elicited by the initial two-dose immunization regime. Broad increases of cellular immunity-associated cytokines and chemokines were also detected in the majority of participants after the third vaccination. Furthermore, in an exploratory study, a newly developed recombinant protein vaccine, NVSI-06-08 (CHO Cells), was found to be safe and even more effective than BBIBP-CorV in eliciting humoral immune responses in BBIBP-CorV-primed individuals. Together, these results indicate that a third immunization schedule with either homologous or heterologous vaccine showed favorable safety profiles and restored potent SARS-CoV-2-specific immunity, providing support for further trials of booster vaccination in larger populations. Electronic Supplementary Material Supplementary material is available in the online version of this article at 10.1007/s11684-021-0914-x and is accessible for authorized users.
Databáze: OpenAIRE
Externí odkaz: